Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals-A randomized double- blind pre-clinical study
- PMID: 30296528
- PMCID: PMC6371811
- DOI: 10.1016/j.bbr.2018.10.010
Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals-A randomized double- blind pre-clinical study
Abstract
Post stroke cognitive impairment (PSCI) is an understudied, long-term complication of stroke, impacting nearly 30-40% of all stroke survivors. No cure is available once the cognitive deterioration manifests. To our knowledge, this is the first study to investigate the long-term effects of C21 treatment on the development of PSCI in aged animals. Treatments with C21 or vehicle were administered orally, 24 h post-stroke, and continued for 30 days. Outcome measures for sensorimotor and cognitive function were performed using a sequence of tests, all blindly conducted and assessed at baseline as well as at different time points post-stroke. Our findings demonstrate that the angiotensin receptor (AT2R) agonist C21 effectively prevents the development of PSCI in aged animals.
Keywords: AT2 receptor; Compound 21; Permanent stroke; Post-stroke cognitive impairment; RAS modulation.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
References
-
- Delavaran H, Jönsson A-C, Lövkvist H, Iwarsson S, Elmståhl S, Norrving B, Lindgren A, Cognitive function in stroke survivors: A 10-year follow-up study, Acta Neurol. Scand. 136(2017) 187–194. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
